CERo Therapeutics Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Net-asset/going-concern-risk value: with 75.92M shares outstanding and a company in severe financial distress (market cap collapsed from over $200M in 2021 to under $1M, recurring dilutive raises just to fund operations), I valued the equity near its current minimal trading level using a liquidation/option-value approach rather than a DCF, since CERo's CAR-macrophage cell-therapy pipeline has no near-term path to revenue and cash runway is the binding constraint.

Reasoning: A discounted cash flow model is not meaningful for a pre-revenue biotech this close to running out of cash and this heavily diluted; the only real source of value is optionality on the pipeline and any future financing or partnership, which I've reflected as a nominal per-share value consistent with its current penny-stock trading range.